Prof Andre Goy talks about his work using inotuzumab ozogamicin and calicheamicin to treat indolent B-cell non-Hodgkin’s lymphoma. The monoclonal antibody inotuzumab ozogamicin was used to deliver calicheamicin, a potent cytotoxic antitumour antibiotic, directly to the surface of tumour cells. Prof Goy describes the patient population that was included in this trial, and explains specifically how the compound affects tumour cells. He also outlines the side effects that were seen in the trial population. The trial produced an overall response rate of 58% and one third of these patients achieved a complete remission.